Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Eledon Pharmaceuticals’ ‘encouraging’ kidney transplant results

Key Takeaway: Eledon Pharmaceuticals has announced promising results from its clinical trials focused on kidney transplants. The data suggests that their treatment may significantly improve outcomes for transplant patients. This development aligns with the company's mission to enhance the quality of life for individuals undergoing organ transplants.
Price reaction · baseline $2.6508 (2025-08-12T18:35:00.000Z) · hit during market hours · 3 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals reported encouraging results in kidney transplant trials.
  • The results indicate potential advancements in organ transplant therapies.
  • The company is focused on transforming lives through innovative treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What results did Eledon Pharmaceuticals report?

Eledon Pharmaceuticals reported encouraging results from its kidney transplant trials.

How do these results impact kidney transplant patients?

The results suggest potential improvements in outcomes for kidney transplant patients.

What is Eledon Pharmaceuticals' mission?

Eledon Pharmaceuticals aims to transform lives through innovative organ transplant therapies.

Last updated: Aug 12, 2025